Core Viewpoint - Alpha Teknova, Inc. is set to report its financial results for Q3 2024 on November 7, 2024, and will host a webcast and conference call for investors [1] Group 1: Company Overview - Teknova has been innovating in the manufacture of critical reagents since 1996, focusing on accelerating the discovery and development of novel therapies [2] - The company provides customizable solutions for various stages of the workflow, supporting sectors such as cell and gene therapy, molecular diagnostics, and synthetic biology [2] - Teknova operates from a headquarters in Hollister, California, with over 200,000 square feet of advanced facilities designed for efficient production [2] Group 2: Financial Reporting - The financial results for the third quarter ended September 30, 2024, will be reported after market close on November 7, 2024 [1] - A live webcast and conference call will take place on the same day at 5:30 p.m. Eastern Time, with a replay available approximately two hours after the event [1]

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Alpha Teknova, Inc. (NASDAQ:TKNO) Q2 2024 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Jennifer Henry - SVP, Marketing Stephen Gunstream - President & CEO Matt Lowell - CFO Conference Call Participants Mark Massaro - BTIG Jacob Johnson - Stephens Steven Mah - TD Cowen Paul Knight - KeyBanc Matt Larew - William Blair Operator Good day and thank you for standing by. Welcome to the Teknova's Second Quarter 2024 Financial Results. At this time, all participants are in a listen-only m ...

| --- | --- | --- | --- | |-------|-----------------------------------------------|-------|-------| | | | | | | | | | | | | FINANCIAL RESULTS: Q2:2024 | | | | | SLIDE SUPPLEMENT Nasdaq: TKNO August 13, 2024 | | | Forward-looking statements and use of non-GAAP financial measures Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, b ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40538 ALPHA TEKNOVA, INC. (Exact name of registrant as specified in its charter) Delaware 94-3368109 (State or other jurisdiction ...

Exhibit 99.1 teknova: Teknova Reports Second Quarter 2024 Financial Results Second quarter 2024 total revenue was $9.6 million, up 3% sequentially Raised $15.4 million of equity capital in July 2024 Launched two new offerings: Express-TekSM Production and RUO+ manufacturing grade Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., August 13, 2024 – Alpha Teknova, Inc. ("Teknova" or the "Company") (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, ...

Second quarter 2024 total revenue was $9.6 million, up 3% sequentially Raised $15.4 million of equity capital in July 2024 Launched two new offerings: Express-TekSM Production and RUO+ manufacturing grade Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and mol ...

HOLLISTER, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2024, on Tuesday, August 13, 2024, following the close of market. About Teknova | --- | --- | |-----------------------------------------|-------| | | | | I ...

HOLLISTER, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2024, on Tuesday, August 13, 2024, following the close of market. About Teknova | --- | --- | |-----------------------------------------|-------| | | | | I ...

The gross proceeds to Teknova from the private placement are approximately $15.4 million, before deducting offering expenses payable by Teknova. Teknova currently intends to use the net proceeds from the private placement for general corporate purposes. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to ...